The earnings call reflected a generally optimistic outlook for COMPASS Pathways, with significant positive results in late-stage trials and a strong financial position. However, challenges remain, particularly in achieving FDA approval and addressing trial dropouts.

Company Guidance -

Q3 2025

During the COMPASS Pathways Second Quarter 2025 Earnings Conference Call, several key metrics and updates were shared. The company reported cash and cash equivalents of $222 million as of June 2025, expected to fund operations into 2027. Debt under the Hercules loan facility stood at $30.9 million. For the second quarter, cash used in operations was $38.7 million, with an anticipated total of $120 million to $145 million for the full year. The company highlighted the successful achievement of the primary endpoint in the COMP360, 005 trial, with a 3.6 point difference in depression reduction from baseline between the 25-milligram and placebo arms at six weeks. This result exceeded the clinically meaningful threshold of a 3-point difference, paralleling the efficacy of SPRAVATO, which required eight administrations. COMPASS Pathways also indicated plans to meet with the FDA to discuss the results and explore accelerated pathways for bringing COMP360 to market. The second pivotal Phase III trial, COMP006, is on track to disclose 26-week data in the second half of 2026. Additionally, the company is preparing for potential commercialization and exploring the treatment's application in PTSD and anorexia, with a Phase II study in anorexia showing an encouraging positive signal in reducing symptoms.

Positive Results in Phase III Trials

COMPASS Pathways announced the successful achievement of the primary endpoint in their COMP360, 005 trial, with highly statistically significant results. The trial demonstrated a 3.6 point reduction in depression from baseline compared to placebo, which is clinically meaningful and commercially viable.

Financial Stability

COMPASS Pathways reported cash and cash equivalents of $222 million, expected to fund operations into 2027, despite a decrease from $260 million at the end of the first quarter.

Expansion into PTSD Treatment

COMPASS Pathways is in the final steps of designing a late-stage clinical program for PTSD, suggesting a significant commercial opportunity given the unmet need in this area.

Potential for Accelerated FDA Approval

The company is actively engaging with the FDA and other stakeholders, exploring accelerated pathways for COMP360 approval, leveraging breakthrough designation and positive preliminary results.

COMPASS Pathways (CMPS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CMPS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.40 / -	-0.56	―	―	―
Jul 31, 2025	2025 (Q2)	-0.43 / -0.41	-0.56	26.79% (+0.15)	―
May 08, 2025	2025 (Q1)	-0.47 / -0.24	-0.55	56.36% (+0.31)	―
Feb 27, 2025	2024 (Q4)	-0.63 / -0.63	-0.53	-18.87% (-0.10)	―
Oct 31, 2024	2024 (Q3)	-0.57 / -0.56	-0.67	16.42% (+0.11)	―
Aug 01, 2024	2024 (Q2)	-0.54 / -0.56	-0.62	9.68% (+0.06)	―
May 08, 2024	2024 (Q1)	-0.48 / -0.55	-0.57	3.51% (+0.02)	―
Feb 29, 2024	2023 (Q4)	-0.36 / -0.53	-0.73	27.40% (+0.20)	―
Nov 02, 2023	2023 (Q3)	-0.52 / -0.67	-0.43	-55.81% (-0.24)	―
Aug 03, 2023	2023 (Q2)	-0.71 / -0.62	-0.5	-24.00% (-0.12)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CMPS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$3.94	$4.35	+10.41%
May 08, 2025	$3.74	$3.76	+0.53%
Feb 27, 2025	$3.70	$3.92	+5.95%
Oct 31, 2024	$6.19	$4.76	-23.10%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does COMPASS Pathways (CMPS) report earnings?

COMPASS Pathways (CMPS) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is COMPASS Pathways (CMPS) earnings time?

COMPASS Pathways (CMPS) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CMPS EPS forecast?

CMPS EPS forecast for the fiscal quarter 2025 (Q3) is -0.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing